12:00 AM
 | 
Sep 30, 2013
 |  BioCentury  |  Finance

Take the money

After IPO at $8, KaloBios dips back at $4 to reach Phase II readouts
Take the money

Despite limping out of the gate with one of the early IPOs of the year, KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) opted to dip back into the markets last week to price a follow-on at $4, which is half of its January IPO price.

KaloBios filed to raise $60 million in an IPO last October and raised $70 million. However, it had to slash the price and jack up the number of shares to do so. The antibody company sold 8.8...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >